These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18173065)

  • 1. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
    Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
    Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
    Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
    Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
    Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
    Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
    Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
    J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
    Song WK; Min YH; Kim YR; Lee SC
    Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.
    Gentile G; Picardi A; Capobianchi A; Spagnoli A; Cudillo L; Dentamaro T; Tendas A; Cupelli L; Ciotti M; Volpi A; Amadori S; Martino P; de Fabritiis P
    BMC Infect Dis; 2006 Nov; 6():167. PubMed ID: 17118205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation.
    Pumannova M; Roubalova K; Vitek A; Sajdova J
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):115-20. PubMed ID: 16406183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
    Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
    Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.
    Bainton RD; Byrne JL; Davy BJ; Russell NH
    Blood; 2002 Nov; 100(10):3843-4. PubMed ID: 12411329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.